首页|依达拉奉右莰醇联合丁苯酞治疗急性缺血性脑卒中合并2型糖尿病的效果及安全性分析

依达拉奉右莰醇联合丁苯酞治疗急性缺血性脑卒中合并2型糖尿病的效果及安全性分析

扫码查看
目的 探究依达拉奉右莰醇联合丁苯酞在急性缺血性脑卒中合并2 型糖尿病中的治疗效果及安全性.方法 选择2019 年7 月—2023 年7 月时间段内治疗的急性缺血性脑卒中合并2 型糖尿病共123 例为研究对象,随机分成2 组.在常规治疗基础上,对照组61 例予以依达拉奉右莰醇治疗,观察组62 例则另外加用丁苯酞治疗.比较2组临床疗效、不良反应发生情况,以及治疗前后改良Rankin量表(mRS)评分、美国国立卫生研究院卒中量表(NIHSS)评分、糖尿病症状控制评价量表(CSSD70)评分、血脂[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)]及血清酶指标[肌酸激酶(CK)、乳酸脱氢酶(LDH)].结果 总有效率,观察组[96.77%(60/62)]相较于对照组[81.97%(50/61)]更高(P<0.05).mRS、NIHSS评分及LDL-C、CK 浓度水平,治疗后观察组相较于对照组更低,而CSSD70 评分和HDL-C浓度水平,则较对照组更高(P<0.05).上述指标观察组治疗前后变化幅度相较于对照组更高(P<0.05).TG、TC、LDH浓度水平及不良反应总发生率,2 组对比并无差异(P>0.05).结论 丁苯酞与依达拉奉右莰醇联合对急性缺血性脑卒中合并2 型糖尿病有较高的疗效,能在保障安全性的基础上有效改善患者临床症状.
Efficacy and Safety of Edaravone Dexborneol Combined with Bu-tylphthalide in the Treatment of Patients with Acute Ischemic Stroke and Type 2 Diabetes Mellitus
Objective To explore the efficacy and safety of Edaravone Dexborneol combined with Butylphthalide in the treatment of acute ischemic stroke(AIS)complicated with type 2 diabetes mellitus(T2DM).Methods A total of 123 patients with AIS complicated with T2DM treated from July 2019 to July 2023 were selected and divided into two groups ran-domly.On the basis of conventional treatment,the control group(n =61)was treated with Edaravone Dexborneol,and the observation group(n =62)was supplemented with Butylphthalide.The clinical efficacy and occurrence of adverse reactions were compared between the two groups.Modified Rankin Scale(mRS)score,National Institutes of Health Stroke Scale(NIHSS)score,Control Status Scale for Diabetes(CSSD70),blood lipids[high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),triglyceride(TG),,total cholesterol(TC)]and serum enzyme-related indexes[creatine kinase(CK),lactate dehydrogenase(LDH)]before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 96.77%(60/62),which was higher than that of the control group[81.97%(50/61)](P<0.05).After treatment,mRS and NIHSS scores as well as LDL-C and CK levels in the ob-servation group were lower than those in the control group,while the CSSD70 scores and HDL-C levels were higher than those in the control group(P<0.05).The changes of the above indexes before and after treatment in observation group were higher than those in control group(P<0.05).After treatment,there was no significant difference in TG,TC,LDH levels as well as total incidence of adverse reactions between the two groups(P>0.05).Conclusion Butylphthalide combined with Edara-vone Dexborneol has a high curative effect on AIS complicated with T2DM,which can effectively alleviate the clinical symp-toms of patients on the basis of ensuring safety.

Acute ischemic strokeType 2 diabetes mellitusEdaravone DexborneolButylphthalideNational Insti-tutes of Health Stroke ScaleModified Rankin ScaleCreatine kinaseLactate dehydrogenase

黄晓勇、沈婧

展开 >

226600 江苏 海安,海安市人民医院神经内科

226600 江苏 海安,海安市人民医院检验科

急性缺血性脑卒中 2 型糖尿病 依达拉奉右莰醇 丁苯酞 美国国立卫生研究院卒中量表 改良Rankin量表 肌酸激酶 乳酸脱氢酶

2024

转化医学杂志
海军总医院

转化医学杂志

CSTPCD
影响因子:0.671
ISSN:2095-3097
年,卷(期):2024.13(2)
  • 19